Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ.
Epperla N, et al. Among authors: bartlett nl.
J Hematol Oncol. 2023 May 8;16(1):49. doi: 10.1186/s13045-023-01448-y.
J Hematol Oncol. 2023.
PMID: 37158890
Free PMC article.